Darling David,Suttie James Miller,Dalphin Mark,Kavalieris Laimonis,O'Sullivan Paul,Kumar Satish
申请号：
US201615159359
公开号：
US10131955(B2)
申请日:
2016.05.19
申请国别(地区):
美国
年份:
2018
代理人:
Borson D. Benjamin`Borson Law Group PC
摘要：
New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients at Low Risk of UC.
